Hisamitsu Pharma Submits NDA For Oxybutynin In Japan
This article was originally published in PharmAsia News
Executive Summary
Hisamitsu Pharma is aiming for 2013 approval of Oxybutynin, the fourth drug being developed for overactive bladder in Japan.